MCID: OVR094
MIFTS: 38

Ovarian Epithelial Cancer

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 53 29 6
Epithelial Ovarian Cancer 53 73
Ovarian Epithelial Carcinoma 53
Ovarian Cancer, Epithelial 53
Eoc 53

Classifications:



Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to ovarian cancer and ovarian cancer 1. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 29.7 CCAT2 ERLNC1 H19 HAGLR HOTAIR MALAT1
2 ovarian cancer 1 11.1
3 functionless pituitary adenoma 10.9 HOTAIR MEG3
4 miyoshi muscular dystrophy 1 10.9 MIR376A1 MIR376C
5 pancreatic neuroendocrine tumor 10.9 MEG3 PIK3CA
6 triple-receptor negative breast cancer 10.8 HOTAIR MALAT1
7 muscular dystrophy, duchenne type 10.8 MIR376A1 MIR376C MIR432
8 muscular dystrophy, limb-girdle, type 2a 10.8 MIR376A1 MIR376C MIR495
9 vulva squamous cell carcinoma 10.8 MALAT1 MEG3
10 esophagus squamous cell carcinoma 10.8 HOTAIR MEG3
11 malignant glioma 10.7 H19 MALAT1 MEG3
12 leiomyoma, uterine 10.7 MIR376B MIR377
13 gastric cardia adenocarcinoma 10.7 H19 HOTAIR MEG3
14 pancreatic ductal adenocarcinoma 10.6 H19 HOTAIR MALAT1
15 prostate disease 10.6 H19 MALAT1 MEG3 PCA3
16 bladder urothelial carcinoma 10.5 HOTAIR MALAT1 MEG3 PIK3CA
17 gastrointestinal system cancer 10.5 H19 HOTAIR MALAT1 PIK3CA
18 clear cell renal cell carcinoma 10.5 CCAT2 MALAT1 MEG3
19 kidney cancer 10.5 H19 HOTAIR MALAT1 MEG3
20 small cell cancer of the lung 10.5 CCAT2 HOTAIR MALAT1 PIK3CA
21 liver cirrhosis 10.5 HOTAIR HULC MALAT1 MEG3
22 astrocytoma 10.5 H19 HOTAIR PCA3
23 osteoarthritis 10.4 H19 HOTAIR MEG3
24 myeloma, multiple 10.4 H19 HOTAIR MALAT1 MEG3
25 gallbladder cancer 10.3 H19 HOTAIR MALAT1 MEG3 PIK3CA
26 leukemia, chronic myeloid 10.3 H19 HOTAIR HULC MEG3
27 lung cancer susceptibility 3 10.3 H19 HOTAIR MALAT1 MEG3 PIK3CA
28 cholangiocarcinoma 10.3 CCAT2 H19 HULC MALAT1 PIK3CA
29 glioblastoma 10.2 H19 HOTAIR MALAT1 MEG3 PIK3CA
30 thyroid cancer 10.2 H19 HOTAIR MALAT1 PIK3CA
31 pituitary adenoma 10.2 CCAT2 H19 HOTAIR MALAT1 MEG3
32 parkinson disease, late-onset 10.2 H19 HOTAIR MALAT1 PCA3
33 oral squamous cell carcinoma 10.2 CCAT2 H19 HOTAIR MALAT1 MEG3
34 squamous cell carcinoma 10.2 CCAT2 H19 HOTAIR MALAT1 PIK3CA
35 lung squamous cell carcinoma 10.2 CCAT2 MEG3 PIK3CA
36 nasopharyngeal carcinoma 10.1 H19 HOTAIR HULC MALAT1 MEG3 PIK3CA
37 esophageal cancer 10.1 H19 HOTAIR HULC MALAT1 MEG3 PIK3CA
38 thyroid cancer, nonmedullary, 1 10.1 H19 HAGLR HOTAIR HULC MALAT1 MEG3
39 neuroblastoma 10.1 H19 HAGLR HOTAIR MALAT1 MEG3 PIK3CA
40 osteogenic sarcoma 10.0 CCAT2 H19 HOTAIR HULC MALAT1 MEG3
41 melanoma 10.0 H19 HOTAIR MALAT1 MEG3
42 pancreatic cancer 9.9 H19 HOTAIR HULC MALAT1 MEG3 MIR376A1
43 sarcoma 9.7
44 endometriosis 9.7
45 type i 9.7
46 hypoxia 9.7
47 endotheliitis 9.7
48 cervical cancer 9.7 CCAT2 H19 HAGLR HOTAIR HULC MALAT1
49 bladder cancer 9.6 CCAT2 H19 HAGLR HOTAIR HULC MALAT1
50 glioma 9.4 CCAT2 H19 HAGLR HOTAIR HULC MALAT1

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 628)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
4
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
5
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
6
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
7
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 151165 6918365
8
Tranexamic Acid Approved Phase 4 1197-18-8 5526
9
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
10
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 5785 54670067
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 11103-57-4, 68-26-8 445354
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
15
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
16 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
18
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Ferrous fumarate Phase 4,Not Applicable,Early Phase 1
20 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 neurokinin A Phase 4,Phase 2,Not Applicable
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Retinol palmitate Phase 4,Phase 1,Phase 2
44 Coagulants Phase 4,Phase 2,Not Applicable
45 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antifibrinolytic Agents Phase 4
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2264)
# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
3 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
8 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
9 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
10 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
11 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
12 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
13 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
14 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
15 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
16 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
17 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
18 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
19 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
20 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
21 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
22 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
23 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
24 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
25 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
26 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
27 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
28 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
29 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
30 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
31 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
32 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
33 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
34 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
35 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
36 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
37 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
38 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
39 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
40 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
41 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
42 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
43 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy Completed NCT00004166 Phase 3 amifostine trihydrate
44 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
45 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
46 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
47 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
48 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
49 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
50 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

41
Lung, Testes, T Cells, Ovary, Bone, Breast, Bone Marrow

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 86)
# Title Authors Year
1
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. ( 29454514 )
2018
2
Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. ( 28685546 )
2017
3
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. ( 29953793 )
2017
4
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. ( 28693156 )
2017
5
Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. ( 29124539 )
2017
6
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. ( 27445438 )
2016
7
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. ( 27017986 )
2016
8
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway. ( 26261554 )
2015
9
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. ( 26554540 )
2015
10
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. ( 26408685 )
2015
11
Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. ( 25609006 )
2015
12
Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. ( 26137074 )
2015
13
Overexpression of Class III I^-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. ( 26198101 )
2015
14
Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study. ( 25768081 )
2015
15
Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. ( 25503164 )
2014
16
Inhibitory role of prohibitin in human ovarian epithelial cancer. ( 24966933 )
2014
17
Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. ( 23708102 )
2013
18
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. ( 23652306 )
2013
19
Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. ( 24133590 )
2013
20
The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. ( 23254909 )
2013
21
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. ( 23189165 )
2012
22
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 22895947 )
2012
23
Over-expression of semaphorin4D, hypoxia-inducible factor-1I+ and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. ( 23202951 )
2012
24
Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. ( 22985132 )
2012
25
Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via I^1 integrin and PTEN signals. ( 23013730 )
2012
26
Novel approaches to quantify estradiol-induced loss of ERI^1 protein in older mouse ovarian surface epithelium: new tools to assess the role of ER protein subtypes in predisposing to ovarian epithelial cancer? ( 21773845 )
2011
27
Ovarian epithelial cancer stem cells. ( 21666993 )
2011
28
High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. ( 20811671 )
2010
29
Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. ( 21074685 )
2010
30
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer. ( 19945796 )
2010
31
A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer. ( 20600897 )
2010
32
[Effects of PTEN over-expression on phosphatidyl inositol 3-kinase/protein kinase B signal pathway in ovarian epithelial cancer cells]. ( 21092549 )
2010
33
Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. ( 19181441 )
2009
34
Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. ( 18676764 )
2008
35
[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. ( 19173805 )
2008
36
Multitargeting ovarian epithelial cancer: adding the old to the new. ( 18349413 )
2008
37
Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. ( 17906381 )
2007
38
Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. ( 17549341 )
2007
39
[Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. ( 17673045 )
2007
40
Two-tier grading system for ovarian epithelial cancer: has its time arrived? ( 17667555 )
2007
41
Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. ( 17712227 )
2007
42
[Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens]. ( 18476518 )
2007
43
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. ( 17943850 )
2007
44
Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. ( 16936295 )
2006
45
Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. ( 16961294 )
2006
46
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. ( 17107625 )
2006
47
Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons. ( 16707225 )
2006
48
Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. ( 15944801 )
2005
49
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. ( 15867369 )
2005
50
Aromatase expression in ovarian epithelial cancers. ( 15748828 )
2005

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
6 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
7 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

Pathways related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Ovarian Epithelial Cancer

Biological processes related to Ovarian Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of sprouting angiogenesis GO:1903671 8.62 MIR377 MIR495

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....